The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

January 1, 2009 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Michele Kaufman is a freelance medical writer based in New York City.

You Might Also Like
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
Explore This Issue
January 2009
Also By This Author
  • Biosimilars for RA Studied in Multiple Trials

References

  1. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007; 18:401-408.
  2. Koumis T, Nathan JP, Rosenberg JM, Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation. Am J Health-Syst Pharm. 2004; 61:515-519.
  3. Pasternak RC, Smith C Jr, Bairney-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33:2337-2341.
  4. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400-409.
  5. Law M, Rudnicka AR. Statin Safety: A systematic review. Am J Cardiol. 2006;97(Suppl):52C-60C.
  6. Slim H, Thompson PD. Ezetimibe-related myopathy: A Systematic review. J Clin Lipidol. 2008;2:328-334.
  7. Christopher-Stine L. Stain myopathy: An update. Curr Opin Rhematol. 2006;16:647-653.
  8. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle – Are all statins the same? Drug Safety. 2002;25:649-663.
  9. Klopstock T. Drug-induced myopathies. Curr Opin Neurol. 2008;21:590-595.
  10. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(suppl):89C-94C.
  11. Link E for the SEARCH Collaborative Group. SCLO1B1 variants and statin-induced myopathy – A genomewide study. N Engl J Med. 2008;359:789-799.
  12. UCB files for R.: www.ucb-group.com/news/3019.asp. Last accessed October 20, 2008.
  13. FDA approves Cimzia to treat Crohn’s disease. www.fda.gov/bbs/topics/NEWS/2008/NEW01821.html. Last accessed October 20, 2008.
  14. EULAR RAPID results: www.medicalnewstoday.com/articles/111632.php Last accessed October 20, 2008.
  15. Additional RA indications/RA in Europe: http://hugin.info/133973/R/1239755/265632.pdf Last accessed October 20, 2008.
  16. BLA submitted for Golimumab. www.drugs.com/nda/golimumab_080627.html. Last accessed October 20, 2008.
  17. Drug Watch. Adult and juvenile rheumatoid arthritis drugs in development. Formulary. 2008;43:260.
  18. FDA issues complete response letter to Roche for ACTEMRA (tocilizumab) biologics license application. www.rocheusa.com/newsroom/current/2008/pr2008091801.html. Last accessed November 4, 2008.
  19. Important drug warning new safety information. www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf. Last accessed October 20, 2008.
  20. Prescribing information. www.fda.gov/medwatch/safety/2008/Rituxan_PI.pdf. Last accessed October 20, 2008.
  21. FDA: manufacturers of TNF-blocker drugs must highlight risk of fungal infections. www.fda.gov/bbs/topics/NEWS/2008/NEW01879.html. Last accessed October 20, 2008.
  22. Information for healthcare professionals Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) www.fda.gov/cder/drug/InfoSheets/HCP/TNF_blockersHCP.htm. Last accessed October 20, 2008.
  23. FDA approves updated labeling for psoriasis drug Raptiva. www.fda.gov/bbs/topics/NEWS/2008/NEW01905.html. Last accessed October 21, 2008.
  24. Prescribing information. www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf. Last accessed October 21, 2008.
  25. Important safety information. www.gene.com/gene/products/information/pdf/raptiva_dhcp.pdf. Last Accessed accessed October 21, 2008.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Labeling Changes, Myopathy, Pharmaceutical Research, SafetyIssue: January 2009

You Might Also Like:
  • Drug Updates: Citalopram hydrobromide, Statins, and More
  • Drug Updates
  • Rheumatology Drug Updates
  • Drug Updates

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)